The field of cell and gene therapy (CGT) has made remarkable strides in recent years, offering new hope to patients across an increasingly wide range of conditions. However, the field’s growth has ...
From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...
Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing and quality control services. SHIRLEY, NY, UNITED ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results